Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Kelly A. Kramer

At a glance: Kelly A. Kramer is Director at Gilead Sciences (GILD). Their latest SEC Form 4, filed Nov 16, 2026, reported a sale of $282K. On file: 0 purchase lines ($0) and 6 sale lines ($2.5M).

Disclosed holdings: about $224K of GILD stock: 1,339 shares reported on their latest Form 4 (filed Nov 16, 2026), valued at the Nov 19, 2026 close of $167.13. This counts only GILD shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

Director at Gilead Sciences, Inc. (GILD)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $2.5M

Kelly A. Kramer's InsiderPrint

6 trades from SEC Form 4 filings, 2025 to 2026, drawn as one fingerprint.

InsiderPrint of Kelly A. Kramer: 6 trades, 2025 to 20262025: 0 buys, 2 sales2026: 0 buys, 4 sales

Reading this print: Almost only sells, trading about 6 times a year, typically $357K a trade; most sales are on a pre-planned 10b5-1 schedule; trades in the same month most years.

  • Bump outward: a purchase (0)
  • Dent inward: a sale (6)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Insiders with a similar print

  1. Larry KrausSvp, Cio · OLLI · 100% match
  2. Richard SteinmeierCEO · LPLA · 100% match
  3. Lee HeesonEvp, Head Of Incyte Intl · INCY · 100% match
  4. Paul Jonathan BrodyCFO · IBKR · 100% match
  5. John A. RoushDirector · AEIS · 100% match

Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.

Reported trades

Filed Stock Type Shares Price Value Since
Nov 16SEC GILDGilead Sciences, Inc. Sell Plan 1,67610,039 held (−14%) $168.23 $282K -0.6%
Nov 16SEC GILDGilead Sciences, Inc. Sell Plan 3,8006,239 held (−38%) $169.44 $644K -1.4%
Nov 16SEC GILDGilead Sciences, Inc. Sell Plan 4,7001,539 held (−75%) $170.49 $801K -2.0%
Nov 16SEC GILDGilead Sciences, Inc. Sell Plan 2001,339 held (−13%) $171.44 $34K -2.5%
Dec 1SEC GILDGilead Sciences, Inc. Sell Plan 2,8061,339 held (−68%) $127.11 $357K +31.5%
Dec 1SEC GILDGilead Sciences, Inc. Sell Plan 2,8051,339 held (−68%) $127.10 $357K +31.5%
  • Sell

    Director Kelly A. Kramer sold $282K of GILD at $168.23 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Kelly A. Kramer sold $644K of GILD at $169.44 — cuts the stake by 38%; pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Kelly A. Kramer sold $801K of GILD at $170.49 — cuts the stake by 75%; pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Kelly A. Kramer sold $34K of GILD at $171.44 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Kelly A. Kramer sold $357K of GILD at $127.11 — cuts the stake by 68%; pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Kelly A. Kramer sold $357K of GILD at $127.10 — cuts the stake by 68%; pre-scheduled 10b5-1 plan sale.

Follow Kelly A. Kramer

Get one email when Kelly A. Kramer files a new purchase or sale. Free.

At most one email a day about Kelly A. Kramer, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.